Boston Scientific Files S-4 for $14.7B Penumbra Acquisition, Details Cash & Stock Terms

summarizeSummary

Boston Scientific filed a detailed S-4 registration statement for its approximately $14.7 billion cash and stock acquisition of Penumbra, Inc., outlining the definitive merger consideration and regulatory commitments.

check_boxKey Events

• Definitive Merger Terms Detailed

  Boston Scientific filed an S-4 detailing the definitive terms of its acquisition of Penumbra, Inc. for approximately $14.7 billion, following the merger agreement dated January 14, 2026.

• Cash and Stock Consideration

  Penumbra shareholders will receive $374.00 per share, with an election for either $274.00 in cash or 3.8721 Boston Scientific shares, subject to proration (73.26% cash, 26.74% stock).

• Financing Secured

  Boston Scientific previously secured $11 billion in new credit facilities on February 26, 2026, to fund the cash portion of the acquisition.

• Regulatory Commitments

  Boston Scientific committed to divest assets generating up to $300 million in revenue (FY2025) if required for regulatory approvals, with HSR filing made on February 13, 2026.

auto_awesomeAnalysis

Boston Scientific filed a detailed S-4 registration statement for its approximately $14.7 billion cash and stock acquisition of Penumbra, Inc., outlining the definitive merger consideration and regulatory commitments. This filing provides the specific terms of the transaction, including the cash and stock components, and details the regulatory pathway, building upon previous disclosures regarding the acquisition and its financing. The acquisition is a substantial strategic move aimed at expanding Boston Scientific's category leadership, though it will result in dilution for existing shareholders. The commitment to divest assets up to $300 million in revenue highlights Boston Scientific's strong intent to secure necessary regulatory approvals.